Home » Authors » Brady Huggett

Articles by Brady Huggett

Igeneon Expands Celltrion Deal For Up To $20M More

Feb. 8, 2006

By Brady Huggett

Maxygen, Roche Enter $95M Recombinant Factor VIIa Deal

Dec. 16, 2005

By Brady Huggett

Maxygen, Roche Enter $95M Recombinant Factor VIIa Deal

Dec. 16, 2005

By Brady Huggett

Gauging State Of European Biotechnology VC Industry

Dec. 5, 2005

By Brady Huggett

Gauging State Of European Biotechnology VC Industry

Dec. 5, 2005

By Brady Huggett

VC Syndication Key For Young European Biotechnology Firms

Dec. 1, 2005

By Brady Huggett

VC Syndication Key For Young European Biotechnology Firms

Dec. 1, 2005

By Brady Huggett

Serenex In-Licenses Phase II Drug, Raises $30M Series C

Oct. 6, 2005

By Brady Huggett

Serenex In-Licenses Phase II Drug, Raises $30M Series C

Oct. 6, 2005

By Brady Huggett

RenaMed Forms Deal With Genzyme For Up To $43M

Sep. 29, 2005

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...